RT Journal Article
SR Electronic
T1 Oral curcumin in elective abdominal aortic aneurysm repair: a multicentre randomized controlled trial
JF Canadian Medical Association Journal
JO CMAJ
FD Canadian Medical Association
SP E1273
OP E1280
DO 10.1503/cmaj.180510
VO 190
IS 43
A1 Amit X. Garg
A1 P.J. Devereaux
A1 Andrew Hill
A1 Manish Sood
A1 Bharat Aggarwal
A1 Luc Dubois
A1 Swapnil Hiremath
A1 Randolph Guzman
A1 Vikram Iyer
A1 Matthew James
A1 Eric McArthur
A1 Louise Moist
A1 George Ouellet
A1 Chirag R. Parikh
A1 Virginia Schumann
A1 Sumit Sharan
A1 Heather Thiessen-Philbrook
A1 Sheldon Tobe
A1 Ron Wald
A1 Michael Walsh
A1 Matthew Weir
A1 Neesh Pannu
A1 Curcumin AAA AKI Investigators
YR 2018
UL http://www.cmaj.ca/content/190/43/E1273.abstract
AB BACKGROUND: Curcumin, a popular herbal supplement from the plant turmeric, has prevented ischemic reperfusion and toxin-induced injury in many animal studies and a single-centre randomized human trial. We sought to test whether perioperative oral curcumin (compared with placebo) affects the inflammatory response and risk of postrepair complications after elective abdominal aortic aneurysm repair in humans.METHODS: We conducted a parallel-group, randomized, placebo-controlled trial of patients from 10 hospitals in Canada who were scheduled to undergo elective repair of an unruptured abdominal aortic aneurysm (November 2011 to November 2014). Patients in the treatment group received perioperative oral curcumin (2000-mg doses 8 times over 4 d). Patients, health care providers and local research staff were unaware of the treatment assignment. The primary outcomes were median concentrations of 4 bio markers indicating injury and inflammation (postoperative urine interleukin-18 and perioperative rise in serum creatinine, plasma N-terminal pro–B-type natriuretic peptide and plasma high-sensitivity C-reactive protein).RESULTS: Baseline characteristics were similar in the 2 groups (606 patients overall; median age 76 yr). More than 85% of patients in each group took more than 80% of their scheduled capsules. Neither curcumin nor placebo significantly affected any of the 4 biomarkers (p > 0.05 for all comparisons). Regarding the secondary outcomes, there was a higher risk of acute kidney injury with curcumin than with placebo (17% v. 10%, p = 0.01), but no between-group difference in the median length of hospital stay (5 v. 5 days, p > 0.9) or the risk of clinical events (9% v. 9%, p = 0.9).INTERPRETATION: Curcumin had no beneficial effects when used in elective abdominal aortic aneurysm repair. These findings emphasize the importance of testing turmeric and curcumin before espousing their health benefits, as is currently done in the popular media.Trial registration: ClinicalTrials.gov, no. NCT01225094.See related article at www.cmaj.ca/lookup/doi/10.1503/cmaj.181358